Post Profile






Astra's Farxiga results may open up type 1 diabetes opportunity

FRANKFURT (Reuters) - AstraZeneca's Farxiga was shown to help type-1 diabetics when added to standard insulin therapy, possibly opening up a additional market opportunity for the type-2 diabetes drug, the British drugmaker said in a statement on Thursday.
read more

share

Related Posts


GSK chases Astra with start of big anemia drug trials

Health : Reuters: Health

LONDON (Reuters) - GlaxoSmithKline has started pivotal trials of an experimental anemia drug, chasing AstraZeneca in the race to develop a medicine that mimics the body's response to high altitude.

Clinical trials, ain't the a bitch! Astra's Crestor drug fails to beat Pfizer's Lipitor - Yahoo!

Medical / Pharmaceutical : PharmaGossip

LONDON/ZURICH (Reuters) - AstraZeneca Plc's key cholesterol drug Crestor failed to beat Pfizer Inc's Lipitor in a head-to-head clinical study, limiting any protection the British company will get as its U.S. rival faces competition ...

Astra, Lilly stick with Alzheimer's approach despite setback

Health : Reuters: Health

FRANKFURT (Reuters) - AstraZeneca will expand its collaboration with Eli Lilly to develop an experimental Alzheimer's drug, sticking with an approach that has been a mainstay of research despite recent setbacks.

AstraZeneca Wins U-Turn On Diabetes Drugâ?¨, Meet Them At Diabetes 2013, 1-2 October, London, United Kingdom

Health : Medical News Today

In final draft guidance published in recent weeks, NICE has recommended dapagliflozin (Forxiga, Bristol-Myers Squibb and Astra Zeneca) for some people with type 2 diabetes. ��The agency changed its position on the drug after req...

Bristol close to selling diabetes stake to Astra for $3 bln -WSJ

Medical / Pharmaceutical : PharmaGossip

Dec 18 (Reuters) - Bristol-Myers Squibb Co is close to selling its stake in a diabetes partnership with AstraZeneca Plc to the British drugmaker in a deal valued at more than $3 billion, the Wall Street Journal reported on Wednesday...

Comments


Copyright © 2016 Regator, LLC